As summarized in Figure 2, a growing body of data indicates that d16HER2 mediates tumor initiation, proliferation, invasion, and stemness and optimal sensitivity to HER2-targeted therapy in HER2-positive BC. Here, ERBB2 is linked to neoplasm.